Hepatitis B Vaccine in Seniors

Hepatitis B Vaccination Clinical Trial

Official title:

Mechanisms of Immunosenescence: A Single-Blinded Comparison of the Location of Vaccine Inoculum, Intramuscular Versus Subcutaneous Adipose Tissue, on the Immune Response of Healthy Elderly Adults to a Recombinant Hepatitis B Surface Antigen Vaccine (Recombivax-HB)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04162223
• Other study ID #: 0199221
• Status: Completed
• Phase: Early Phase 1
• Start date: March 29, 2000
• Est. completion date: May 20, 2003

Study information

• Verified date: November 2019
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The first purpose of this study is to test the body's protective reaction (making antibodies) to a licensed hepatitis B vaccine (Recombivax-HB) after it is injected either in the arm fat or muscle. Hepatitis B virus is an important cause of liver disease in humans. More than 21% of healthy adults over age 60 years demonstrate evidence of previous Hepatitis B infection using a common blood test.

The second purpose of this study is to learn more information about other reasons (such as body fat content, gene types, etc.), why older people respond less well than younger people to vaccines. The Investigators will also learn more about the ability of certain white blood cells, called T cells, to respond to protein signals in the blood. T cells do not seem to respond as well to these protein signals as individuals age. The Investigators will compare results to a younger group of volunteers who have also been vaccinated with hepatitis B vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: May 20, 2003
• Est. primary completion date: May 20, 2003
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Healthy, community-dwelling adult men or women 65 years of age or older, of any race or ethnic group

• Medical history with stable chronic non-immunologically mediated medical conditions (e.g. osteoarthritis, hypertension)

• Normal (within the normal range for reference laboratory or clinically insignificant values as determined by the Principal Investigator) TSH, serum vitamin B12, AST/SGOT, ALT/SGPT

• Negative serum tests for hepatitis B surface antigen and antibody, hepatitis B core antibody and hepatitis C antibody

• Has given informed consent

• Ready access to a telephone

Exclusion Criteria:

• Clinically apparent or history of immunologically mediated diseases (e.g. rheumatoid arthritis, lupus erythematosis, etc.), immunodeficiency, severe cardiovascular disease, severe respiratory disease (requiring supplemental oxygen), endocrine disorder (e.g. thyroid dysfunction, adrenal insufficiency), liver disease (cirrhosis), renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder (eligible if treated and in remission), drug or alcohol abuse or currently smoking 10 cigarettes per day

• Infections within 2 weeks of immunization (the most frequent infections are respiratory and urogenital)

• Inflammatory processes such as known chronic infections, inflammatory bowel disease or Westergren sedimentation rate (greater than 50mm/hour for men, greater than 60mm/hour for women)

• All malignancies (excluding non-melanotic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years

• Arteriosclerotic event during the 2 weeks prior to enrollment (e.g. medically documented myocardial infarction, stroke, recanalization of the femoral arteries, claudication, or Transient Ischemic Attack (TIA))

• Cardiac insufficiency, if heart failure present (New York Heart Association functional class III or IV)

• Poorly controlled hypertension (Systolic Blood Pressure 180mmHg, Diastolic Blood Pressure 100mmHg on two separate determinations at least 10 minutes apart)

• Renal Insufficiency (serum creatinine 2.0 or BUN 40) and stable over past 6 months

• Elevated or low glucose (fasting 140 or less than 70, non-fasting 200)

• Cognitive impairment: score of less than 23 on the Folstein Mini-Mental State Examination

• Depression or mood alteration: score of 6 on the Geriatric Depression Scale

• Malnutrition as defined by clinical judgment and by decreased serum albumin (less than 3.2g/L) or hypocholesterolemia (less than 160mg/dL), or low total lymphocyte count (less than 1500/ml3)

• Anemia (Hct less than 30% or low serum vitamin B12 or vitamin E level)

• History of or current alcoholism or consuming greater than 2oz of ETOH/day; current drug abuse; currently smoking 10 cigarettes per day

• Risk factors for hepatitis B (which would indicate the need for immediate immunization with licensed vaccine), such as parenteral drug abuse, multiple sexual partners, commercial sex worker, health care worker

• History of hepatitis B infection or vaccination

• Positive test for hepatitis B surface antigen or antibody, hepatitis B core antibody, or hepatitis C antibody

• History of significant bilateral upper arm injury or surgery, of any duration, because theoretically this may impede lymph drainage to regional lymph nodes

• Reported allergy to thimerosal (i.e., contact lens solution) or yeast products

• Unable to attend the Baltimore VA Medical Center or the Waxter Center on a regular basis; no telephone in primary residence

• Subcutaneous fat pad less than 6 mm in thickness as determined by computer tomography

• Medication exclusions include prednisone greater than 5 mg/day (or equal), colchicines, imuran, methotrexate, azathioprine, cyclophosphamide, cyclosporine, or interferons

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B Vaccination

Intervention

Biological:
• Subcutaneous fat injection of Recombivax-HB
Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
• Intramuscular injection of Recombivax-HB
Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.

Locations

Country	Name	City	State
United States	University of Maryland, Baltimore, Center for Vaccine Development and Global Health	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hepatitis B surface antibody (HBsAb) titers (in international units/L)	Basic science - Primary and booster hepatitis B surface antibody titers to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders	two years
Primary	Cell-mediated immune responses (CMI) (levels of interferon gamma and other cytokines in pg/ml)	Basic science - Primary and booster CMI responses to three injections of Recombivax-HB in the elderly and young adults immunized subcutaneously or intramuscularly, including % responders	two years